Session of 2005

HOUSE BILL No. 2397

By Committee on Appropriations

2-9

9 AN ACT concerning distribution of certain prescription drugs; enacting 10 the wholesale licensure and prescription medication integrity act. 11 12Be it enacted by the Legislature of the State of Kansas: 13 Section 1. Sections 1 through 7, and amendments thereto, shall be 14known and may be cited as the "wholesale licensure and prescription 15 medication integrity act". 16Sec. 2. As used in the wholesale licensure and prescription integrity 17act: 18"Authentication" means to affirmatively verify before any distri-(a) 19bution of a prescription drug occurs that each transaction listed on the 20pedigree has occurred. 21"Facility" means a facility of a wholesale distributor where pre-(b) 22 scription drugs are stored, handled, repackaged or offered for sale. 23 (c) "Immediate family" shall include a person's spouse, children, par-24 ents, siblings, the spouses of a person's children and the spouses of a 25person's siblings. 26"Normal distribution channel" means a chain of custody for a (d) 27 medication that goes from a manufacturer to a wholesaler to a pharmacy 28 to a patient. 29 (e) "Pedigree" means a document or electronic file containing infor-30 mation that records each distribution of any given prescription drug, from 31sale by a pharmaceutical manufacturer, through acquisition and sale by 32 any wholesale distributor or repackager, until final sale to a pharmacy or 33 other person dispensing or administering the prescription drug. 34 "Prescription drug" means any drug, including any biological (f) 35 product, except for blood and blood components intended for transfusion 36 or biological products that are also medical devices required by federal 37 law or regulations, to be dispensed only by a prescription, including fin-38 ished dosage forms and bulk drug substances subject to section 503(b) of 39 the federal food, drug and cosmetic act (FFDCA). 40 "Repackage" means repackaging or otherwise changing the con-(g) 41tainer, wrapper or labeling to further the distribution of a prescription 42drug. 43 (h) "Repackager" means a person who repackages.

21

29

(i) "Wholesale distributor" means anyone engaged in the wholesale
distribution of prescription drugs, including, but not limited to, manufacturers unless specified otherwise; repackagers; own-label distributors; private-label distributors; jobbers; brokers; warehouses, including manufacturers' and distributors' warehouses; chain drug warehouses and
wholesale drug warehouses; independent wholesale drug traders; and retail pharmacies that conduct wholesale distribution.

8 Sec. 3. (a) Every wholesale distributor which engages in the whole-9 sale distribution of prescription drugs in the state shall be licensed by the 10 state licensing authority in the state in which it resides and every non-11 resident wholesale distributor shall be licensed in the state if it ships 12 prescription drugs into the state in accordance with the wholesale licen-13 sure and prescription medication integrity act before engaging in whole-14 sale distribution of wholesale prescription drugs in the state.

(b) In addition to any other requirement prescribed by law, the state
board of pharmacy shall require the following minimum information from
each wholesale distributor applying for a license under this section and
as a part of any renewal of such license:

(1) The name, full business address and telephone number of the
 applicant or licensee;

(2) all trade or business names used by the applicant or licensee;

(3) addresses, telephone numbers and names of contact persons for
all facilities used by the applicant or licensee for the storage, handling
and distribution of prescription drugs;

(4) The type of ownership or operation, including, but not limited to,
partnership, corporation or sole proprietorship;

(5) The name or names of the owner or operator of the licensee orapplicant and related information, including:

(A) If an individual, the name of the individual;

30 (B) if a partnership, the name of each partner and the name of the 31 partnership;

(C) if a corporation, the name and title of each corporate officer and
 director, the corporate names and the state of incorporation; and

(D) if a sole proprietorship, the full name of the sole proprietor andthe name of the business entity;

36 (6) a list of all licenses and permits issued to the applicant or licensee
37 by any other state that authorizes the applicant or licensee to purchase
38 or possess prescription drugs;

(7) the name of the manager of the facility that is applying for the
initial license or to renew the license, the next four highest ranking employees responsible for prescription drug wholesale operations for the
facility, and the name of all affiliated parties for the facility, together with

43 the personal information statement required pursuant to subsection

10

37

1 (b)(9) of this section and fingerprints for each of such persons;

2 (8) the name of the designated representative of the applicant or 3 licensee for the facility and the personal information statement required 4 pursuant to subsection (b)(9) of this section and fingerprints for such 5 person; and

6 (9) the following information for each person described in paragraph 7 (b)(7) or (b)(8) of this section required to provide a personal information 8 statement and fingerprints shall provide the following information to the 9 state:

(A) The person's places of residence for the past seven years;

11 (B) the person's date and place of birth;

12 (C) the person's occupations, positions of employment and offices 13 held during the past seven years;

(D) the principal business and address of any business, corporation
or other organization in which each such office of the person was held or
in which each such occupation or position of employment was held;

(E) whether the person has been, during the past seven years, the
subject of any proceeding for the revocation of any license and, if so, the
nature of the proceeding and the disposition of the proceeding;

(F) whether, during the past seven years, the person has been enjoined, either temporarily or permanently, by a court of competent jurisdiction from violating any federal or state law regulating the possession,
control or distribution of prescription drugs, together with details concerning any such event;

(G) a description of any involvement by the person with any business,
including any investments, other than the ownership of stock in a publicly
traded company or mutual fund, during the past seven years, which manufactured, administered, prescribed, distributed or stored pharmaceutical
products and any lawsuits in which such businesses were named as a party;

(H) a description of any felony criminal offense of which the person,
as an adult, was found guilty, regardless of whether adjudication of guilt
was withheld or whether the person pled guilty or nolo contendere. If
the person indicates that a criminal conviction is under appeal and submits a copy of the notice of appeal of that criminal offense, the applicant
or licensee must, within 15 days after the disposition of the appeal, submit
to the state a copy of the final written order of disposition; and

(I) A photograph of the person taken in the previous 30 days.

(c) The information required pursuant to subsection (b) of this sec-tion shall be provided under oath.

(d) The board of pharmacy shall not issue or renew a wholesale distributor license of an applicant or licensee unless the state board of pharmacy determines that the designated representative meets the following
qualifications:

1 (1) Is at least 21 years of age;

(2) has been employed full time for at least three years in a pharmacy
or with a wholesale distributor in a capacity related to the dispensing and
distribution of and recordkeeping relating to prescription drugs;

5 (3) has received a score of 75% or more on an examination given by 6 the state board of pharmacy regarding federal and state laws governing 7 wholesale distribution of prescription drugs. A designated representative 8 who has previously served in such capacity shall retake the state exami-9 nation each time a licensee lists the person as the designated represen-10 tative in an application for license renewal;

11 (4) is employed by the applicant full time in a managerial level 12 position;

(5) is actively involved in and aware of the actual daily operation ofthe wholesale distributor;

(6) is physically present at the facility of the applicant during regular
business hours, except when the absence of the designated representative
is authorized, including, but not limited to, sick leave and vacation leave;

(7) is serving in the capacity of a designated representative for onlyone applicant or licensee at a time;

(8) does not have any convictions under any federal, state or local
laws relating to wholesale or retail prescription drug distribution or distribution of controlled substances; and

23 (9) does not have any felony convictions under federal, state, or local24 laws.

(e) The state board of pharmacy shall submit the fingerprints provided by a person with an initial or a renewal license application for a
statewide criminal history record check and for forwarding to the federal
bureau of investigation for a national criminal history record check of the
person.

(f) The state board of pharmacy shall require every wholesale distrib-30 utor applying for a new license or the renewal of a license to submit a 3132 bond in an amount determined by the state board of pharmacy or other equivalent means of security acceptable to the state board of pharmacy, 33 34 such as an irrevocable letter of credit or a deposit in a trust account or 35 financial institution, payable to the drug wholesaler trust fund established 36 pursuant to subsection (g). The purpose of the bond is to secure payment 37 of any fines or penalties imposed by the state board of pharmacy and any 38 fees and costs incurred by the state board of pharmacy regarding that 39 license which are authorized under the wholesale licensure and prescrip-40 tion medication integrity act and which the licensee fails to pay 30 days after the fines, penalties or costs become final. The state board of phar-4142macy may make a claim against such bond or security until one year after

43 the licensee's license ceases to be valid.

HB 2397

1 (g) There is hereby created in the state treasury the drug wholesaler trust fund. The executive secretary of the state board of pharmacy shall 2 3 administer the fund. Proceeds from the bond prescribed by subsection (f) of this section shall be remitted to the state treasurer in accordance 4 with the provisions of K.S.A. 75-4215, and amendments thereto. Upon $\mathbf{5}$ receipt of each such remittance the state treasurer shall deposit the entire 6 7 amount in the state treasury to the credit of the drug wholesaler trust 8 fund. Moneys in the drug wholesaler trust fund may be expended for the purposes prescribed in subsection (h) of this section. All expenditures 9 from the drug wholesaler trust fund shall be made in accordance with 10 appropriation acts upon warrants of the director of accounts and reports 11 12issued pursuant to vouchers approved by the executive secretary of the 13 state board of pharmacy.

(h) If a wholesale distributor distributes prescription drugs frommore than one facility, the wholesale distributor shall obtain a license foreach facility.

(i) Changes in any information in subsection (b) shall be submittedto the board of pharmacy as required by such board.

Sec. 4. (a) On and after the effective date of this act, in any calendar
month, a wholesale distributor shall sell, distribute, transfer or otherwise
sell at least 95% of its total amount of prescription drugs to a pharmacy
or other person dispensing or administering the drug.

(b) A wholesale distributor shall not purchase or otherwise receive a
prescription drug from a pharmacy, except that a wholesale distributor
may receive a prescription drug from a pharmacy if the prescription drug
was originally purchased by the pharmacy from the wholesale distributor.

(c) A wholesale distributor which meets the exception in subsection(b) shall not:

(1) Receive from a pharmacy an amount or quantity of a prescription
drug larger than the amount or quantity that was originally sold by the
wholesale distributor to the pharmacy; or

(2) pay the pharmacy an amount, either in cash or credit, more than
the pharmacy originally paid the wholesale distributor for the prescription
drug.

(d) A manufacturer or wholesale distributor shall furnish prescription drugs only to a person licensed by the appropriate state licensing authorities. Before furnishing prescription drugs to a person not known to the manufacturer or wholesale distributor, the manufacturer or wholesale distributor shall affirmatively verify the person is legally authorized to receive the prescription drugs by contacting the appropriate state licensing authorities.

42 (e) Prescription drugs furnished by a manufacturer or wholesale dis-43 tributor shall be delivered only to the premises listed on the license, 1 provided that the manufacturer or wholesale distributor may furnish pre-

2 scription drugs to an authorized person or agent of that person at the 3 premises of the manufacturer or wholesale distributor if:

4 (1) The identity and authorization of the recipient is properly estab-5 lished; and

6 (2) this method of receipt is employed only to meet the immediate 7 needs of a particular patient of the authorized person.

8 Prescription drugs may be furnished to a hospital pharmacy receiving 9 area provided that a pharmacist or authorized receiving personnel signs, at the time of delivery, a receipt stating the type and quantity of such 10 prescription drug, or drugs received. Any discrepancy between the receipt 11 12and the type and quantity of the prescription drug actually received shall be reported to the delivering manufacturer or wholesale distributor on 13 or before the next business day after the delivery to the pharmacy re-1415 ceiving area.

16 (f) A manufacturer or wholesale distributor shall not accept payment 17 for, or allow the use of, a person or entity's credit to establish an account 18 for the purchase of prescription drugs from any person other than the 19 owner or owners or record, the chief executive officer or the chief finan-20 cial officer listed on 1he license of a person or entity legally authorized 21 to receive prescription drugs. Any account established for the purchase 22 of prescription drugs shall bear the name of the licensee.

23 Sec. 5. (a) Each person who is engaged in the wholesale distribution of a prescription drug, including repackagers, but excluding the original 24 manufacturer of the finished form of the prescription drug, shall provide 2526a pedigree or electronic file identifying each sale, trade or transfer of a 27prescription drug when a prescription drug leaves the normal distribution 28channel and is sold, traded or transferred to any other person. If a phar-29 macy sells a drug to any person who is not the final consumer, the phar-30 macy shall provide to the person acquiring the prescription drug a pedi-31gree identifying each sale, trade or transfer of a prescription drug. Sale, 32 trade or transfer of a prescription drug between licensees with a common 33 ownership or to meet emergency needs are not subject to the provisions 34 of this section.

(b) Each person who is engaged in the wholesale distribution of a prescription drug, including repackagers, but excluding the original manufacture of the finished form of the prescription drug, who is in possession of a pedigree for a prescription drug and attempts to further distribute such prescription drug, shall affirmatively verify before any distribution of a prescription drug occurs that each transaction listed on the pedigree has occurred.

42 (c) The pedigree shall:

43 (1) Include all necessary identifying information concerning each sale

1 in the chain of distribution of the product from the manufacture, through

acquisition and sale by any wholesale distributor or repackager, until final
sale to a pharmacy or other person dispensing or administering the drug.

4 The necessary chain of distribution information shall include, but shall 5 not be limited to:

6 (A) The name, address, telephone number and if available, the e-mail 7 address, of each owner of the prescription drug, and each wholesale dis-8 tributor who does not take title to the prescription drug;

9 (B) the signature of each owner of the prescription drug and each 10 wholesale distributor who does not take title to the prescription drug;

11 (C) the name and address of each location from which the product 12 was shipped, if different from the owner's;

13 (D) the transaction dates; and

14 (E) certification that each recipient has authenticated the pedigree.

15 (2) The pedigree shall also include, but shall not be limited to:

16 (A) The name of the prescription drug;

17 (B) dosage form and strength of the prescription drug;

18 (C) size of the container;

19 (D) number of containers;

20 (E) lot number of the prescription drug; and

21 (F) name of the manufacturer of the finished dosage form.

22 (d) Each statement shall be:

(1) Maintained by the purchaser and the wholesale distributor forthree years; and

(2) available for inspection or removal upon a request of an author-ized officer of the law.

(e) The state board of pharmacy administering this act shall adopt
rules and a form relating to the requirements of this section on or before
90 days after the effective date of this act.

30 Sec. 6. (a) If the state finds that there is a reasonable probability that:

31 (1) A wholesale distributor has:

32 (A) Knowingly violated a provision of this act; or

(B) falsified a pedigree, or knowingly sold, distributed, transferred,
 manufactured, repackaged, handled or held a counterfeit prescription
 drug intended for human use.

36 (2) The prescription drug which is alleged to be in violation of par37 agraph (1) of subsection (a) of this section could cause serious adverse
38 health consequences or death; and

(3) other procedures would result in unreasonable delay, the state
shall issue an order requiring the appropriate person, including the manufacturers, distributors or retailers of the drug, to immediately cease distribution of the drug.

43 (b) An order issued under paragraph (3) of subsection (a) of this sec-

1 tion shall provide the person subject to the order with an opportunity for an informal hearing, to be held on or before 10 days after the date of the 2 3 issuance of the order, on the actions required by the order. If, after providing an opportunity for such a hearing, the state determines that in-4 adequate grounds exist to support the actions required by the order, the $\mathbf{5}$ state shall vacate the order. 6 7 Sec. 7. (a) It shall be unlawful for a person to perform or cause the 8 performance of or aid and abet any of the following acts in this state: (1) Failure to obtain a license in accordance with this act, or operating 9 without a valid license when a license is required by this act; 10selling, distributing, transferring or otherwise providing prescrip-11 (2)12tion drugs in violation of the 5% rule established in subsection (a) of 13 section 4: purchasing or otherwise receiving a prescription drug from a 14(3)15pharmacy, unless the requirements in subsection (a) of section 3 are met; (4) the sale, distribution or transfer of a prescription drug to a person 16that is not authorized under the law of the jurisdiction in which the person 17receives the prescription drug to receive the prescription drug, in viola-18 tion of subsection (c) of section 3; 1920(5) failure to deliver prescription drugs to specified premises, as re-21quired by subsection (d) of section 3; 22 accepting payment or credit for the sale of prescription drugs in (6)23 violation of subsection (e) of section 3; failure to maintain or provide pedigrees as required by this act; 24 (7)25(8)failure to obtain, pass or authenticate a pedigree, as required by 26 this act: 27 (9) providing the state or any of its representatives or any federal 28official with false or fraudulent records or making false or fraudulent 29 statements regarding any matter under the provisions of this act; 30 (10) obtaining or attempting to obtain a prescription drug by fraud, deceit, misrepresentation or engaging in misrepresentation or fraud in 3132 the distribution of a prescription drug; (11) the manufacture, repacking, sale, transfer, delivery, holding or 33 34 offering or sale any prescription drug that is adulterated, misbranded, 35 counterfeit, suspected of being counterfeit or has otherwise been rendered unfit for distribution; 36 37 (12) the adulteration, misbranding or counterfeiting of any prescrip-38 tion drug;

(13) the receipt of any prescription drug that is adulterated, misbranded, stolen, obtained by fraud or deceit, counterfeit or suspected of
being counterfeit and the delivery or proffered delivery of such drug for
pay or otherwise; and

43 (14) the alteration, mutilation, destruction, obliteration or removal of

1 the whole or any part of the labeling of a prescription drug or the com-

2 mission of any other act with respect to a prescription drug that results 3 in the prescription drug being misbranded.

4 (b) A person convicted of violating subsection (a) shall be guilty of a 5 severity level 1 felony.

6 (c) This section shall be part of and supplemental to the Kansas crim-7 inal code.

8 Sec. 8. This act shall take effect and be in force from and after its9 publication in the statute book.